Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1 R2 R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases especially Type II diabetes and other diseases as set out herein employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such...

A combination comprising 2 to 8 mg of 5-[4-[2-(N-methyl-N- (2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-24-dione (rosiglitazone) or a tautomeric form thereof or a pharmaceutically acceptable salt or solvate thereof; and sub maximal amount of sulphonylurea selected from glibenclamide glipizide gliclazide tolazamide tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide. Disclosed is also a medical use of the co...

Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular the chalcone compound bound with 2-hydroxyl in ring A and 4'-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPAR &ggr; inducer p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition the chalcone compound exhibits synergistic effect with the PPAR &ggr; ligand ...

PURPOSE: A pharmaceutical composition containing a thiazolidinedione-based drug for preventing and treating Alzheimer's disease is provided to enhance LRP1 expression and the discharge of beta-amyloid into the blood. CONSTITUTION: A pharmaceutical composition for treating neurological disorders contains a thiazolidinedione-based drug as an active ingredient. The thiazolidinedione-based drug includes rosiglitazone pioglitazone or troglitazone. The pharmaceutical composition enhances the LRP1 expr...

Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4'-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPAR[gamma] inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPAR[gamma] li...

Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition the chalcone compound exhibits synergistic effect with the PPARγ...